Pamela Vig, Ph.D.

Chief Scientific Officer and Head of Research

Pamela Vig, Ph.D. is a co-founder of Mirum and serves as chief scientific officer and head of research. She is responsible for medical and scientific affairs, non-clinical and research initiatives.

Pam has more than 30 years of industry experience in clinical development, medical affairs and translational science in various liver diseases including hepatitis B (HBV), hepatitis C (HCV), nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and cholestatic liver disease, as well as HIV and other infectious diseases. Before joining Mirum, Pam held leadership roles at Allergan plc and Tobira Therapeutics as vice president of clinical research and discovery, as well as vice president of clinical research at Presidio Pharmaceuticals, Inc. Pam previously served as director, global medical affairs, at Johnson & Johnson in London, UK, and also held positions in clinical research and development at Idenix Pharmaceuticals and Gilead Sciences, Inc. Pam is the industry co-chair for the PSC Forum Steering Committee as well as co-chair for the Pediatric Cholestatic Disease working Group under the Forum for Collaborative Research.

Pam holds a Ph.D. from Imperial College London in the departments of hepatology and histopathology.